• Mass General Brigham Ventures

Amolyt Pharma to Present New Phase 1 Data on AZP-3601-

- Its Parathyroid Hormone Analog for Hypoparathyroidism, and Preclinical Data on AZP-3404 at Upcoming Scientific Conferences


New data from all cohorts of Phase 1 Single Ascending Dose clinical trial accepted for oral presentation at e-ECE 2021


LYON, France and CAMBRIDGE, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global pharmaceutical company specializing in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that it will be presenting four abstracts at the 23rd European Congress of Endocrinology (e-ECE) 2021 to be held virtually from May 22-26, 2021 as well as an abstract at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 to be held virtually from May 17-20, 2021. At e-ECE 2021, Amolyt Pharma will present new data from all cohorts from its Phase 1 Single Ascending Dose clinical trial evaluating AZP-3601, a parathyroid hormone (PTH) analog specifically designed for the treatment of hypoparathyroidism. In addition, Amolyt will present two retrospective Natural History Study methods to identify patients with chronic hypoparathyroidism. Finally, Amolyt will present preclinical data for AZP-3404, a peptide with a new and unique potential mechanism of action on fat and glucose metabolism. At ISPOR 2021, Amolyt will present proposed methods to identify patients with chronic hypoparathyroidism using claims data in the United States (US). Details of the abstracts are as follows:

ISPOR 2021 Poster Presentation Title: Methods to Identify Patients with Chronic Hypoparathyroidism in the United States (US) Using Claims Data Session: Virtual Poster Discussion Session 3, Rare & Orphan Diseases, Methodological & Statistical Research Session Date/Time: Wednesday, May 19, 2021 from 11:30 AM – 1:45 PM EDT

e-ECE 2021 Oral Presentations Title: Safety, Tolerability and Pharmacodynamics of AZP-3601, a Novel Long-Acting PTH Analog, in Healthy Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study Session: Channel 1, Oral Communications 6: Calcium and Bone Session Date/Time: Tuesday, May 25, 2021 from 14:30 – 15:30 CET Title: Improved Glucose Metabolism and Decreased Weight Gain in Leptin-Resistant, IGFBP2-Deficient, db/db Mice Induced by AZP-3404, a 9-Amino Acid Analog of IGFBP2 Session: Channel 2, Oral Communications 12: Diabetes, Obesity, Metabolism and Nutrition Session Date/Time: Wednesday, May 26, 2021 from 14:30 – 15:30 CET

e-ECE 2021 Poster Presentations Title: Assessment of Clinical Burden and Practice Patterns in Patients with Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis-Based Criteria Session: Thyroid (non cancer)

Title: Assessment of Clinical Burden and Practice Patterns in Patients with Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using a Surgery-Based Approach Session: Thyroid (non cancer) Additional details can be found on the ISPOR and e-ECE websites and copies of the presentations and abstracts will be available on the Amolyt website once the presentations conclude.

To learn more: Amolyt Pharma to Present New Phase 1 Data on AZP-3601, its Parathyroid Hormone Analog for Hypoparathyroidism, and Preclinical Data on AZP-3404 at Upcoming Scientific Conferences

Related Posts

See All